European Economic News Preview: Eurozone Unemployment Data Due

Unemployment data from the euro area, Spain and Italy are due on Wednesday, headlining a light day for the European economic news.

At 3.00 am ET, Spain’s monthly unemployment data for April is due. The number of people out of work had decreased 48,755 in March.

At 4.00 am ET, Italy’s Istat is scheduled to issue unemployment data for March. The jobless rate is seen unchanged at 8.0 percent.

At 5.00 am ET, Eurozone unemployment report is due from Eurostat. Economists forecast the jobless rate to stay at 6.6 percent in March.

At 8.30 am ET, the Czech National Bank announces its monetary policy decision. The bank is expected to hold its key rate at 7.00 percent.

Arrowhead Pharma Stock Up 8% On Quarterly Results

Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) are gaining over 8% on Wednesday morning after reporting second-quarter results.

ARWR is currently trading at $38.38, up $3.00 or 8.48%, on the Nasdaq. The stock opened its trading at $35.46 after closing Tuesday’s trading at $35.38. The stock has traded between $23.09 and $48.48 in the past 52-week period.

Net income for the quarter rose to $48.7 million or $0.45 per share from $44.4 million or $0.41 per share last year. Revenues for the quarter slipped to $146.3 million from $151.8 million last year. Analysts polled by Thomson Reuters had expected the company to report a loss of $0.64 per share.

Immix Biopharma Stock Slips 16%

Shares of Immix Biopharma, Inc. (IMMX) are slipping over 16% on Wednesday morning despite positive interim clinical trial data of colorectal cancer treatment.

IMMX is currently trading at $2.4200, down $0.4800 or 16.5517%, on the Nasdaq. The stock opened its trading at $2.6800 after closing Tuesday’s trading at $2.9000. The stock has traded between $0.6800 and $3.4500 in the past 52-week period.

Immix Biopharma announced positive early interim clinical trial data, which demonstrated 100% tumor shrinkage at 2-months in advanced metastatic colorectal cancer demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 antibody tislelizumab combination in the first cohort of patients who received the lowest IMX-110 dose in its ongoing dose escalation 1b/2a clinical trial of IMX-110 + anti-PD-1 antibody tislelizumab.

“We are excited to see 100% tumor shrinkage in the very first cohort at the lowest dose of IMX-110 in combination with anti-PD-1 antibody tislelizumab in our ongoing IMMINENT-01 dose escalation trial, especially in patients with advanced colorectal cancer, who have limited treatment options,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “These initial results potentially validate the scientific rationale for the promise of IMX-110 to unlock our immune system’s ability to fight cancer.”

Enel Q1 Profit Down

Enel (ENLAY.PK,EN) reported that its first quarter profit attributable to owners of the parent dropped to 1.03 billion euros or 0.10 euros per share from 1.43 billion euros or 0.14 euros per share last year.

Revenues in the first quarter totaled 26.41 billion euros, down from 34.14 billion euros last year.

EBITDA rose 4.7% to 4.77 billion euros from 4.55 billion euros last year.

Colfax Avenue closed east of downtown Denver for motorcycle crash

A motorcycle crash east of downtown Denver on Wednesday morning forced the closure of Colfax Avenue in both directions around Congress Park.

Denver police were investigating the crash, which involved a single motorcyclist and caused serious injuries, near the intersection of Colfax and Adams Street, the police said in a posting on Twitter. Colfax is closed at Steele Street for the investigation.

Police advised drivers to find other routes.

Sign up to get crime news sent straight to your inbox each day.

Ansys Inc Q1 Profit Increases, beats estimates

Ansys Inc (ANSS) reported a profit for its first quarter that increased from the same period last year and beat the Street estimates.

The company’s earnings totaled $100.62 million, or $1.15 per share. This compares with $70.99 million, or $0.81 per share, in last year’s first quarter.

Excluding items, Ansys Inc reported adjusted earnings of $161.76 million or $1.85 per share for the period.

Analysts on average had expected the company to earn $1.61 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 19.8% to $509.45 million from $425.08 million last year.

Ansys Inc earnings at a glance (GAAP) :

-Earnings (Q1): $100.62 Mln. vs. $70.99 Mln. last year.
-EPS (Q1): $1.15 vs. $0.81 last year.
-Analyst Estimate: $1.61
-Revenue (Q1): $509.45 Mln vs. $425.08 Mln last year.

-Guidance:
Next quarter EPS guidance: $1.35 – $1.53
Next quarter revenue guidance: $473.0 – $498.0 Mln
Full year EPS guidance: $8.39 – $8.91
Full year revenue guidance: $2,242 – $2,322 Mln

Sturm Ruger & Co Inc Q1 Profit Declines, misses estimates

Sturm Ruger & Co Inc (RGR) announced earnings for first quarter that decreased from last year and missed the Street estimates.

The company’s earnings totaled $14.35 million, or $0.81 per share. This compares with $30.23 million, or $1.70 per share, in last year’s first quarter.

Analysts on average had expected the company to earn $0.97 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter fell 10.3% to $149.45 million from $166.58 million last year.

Sturm Ruger & Co Inc earnings at a glance (GAAP) :

-Earnings (Q1): $14.35 Mln. vs. $30.23 Mln. last year.
-EPS (Q1): $0.81 vs. $1.70 last year.
-Analyst Estimates: $0.97
-Revenue (Q1): $149.45 Mln vs. $166.58 Mln last year.